Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 15/20 | 0.45 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.43 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.43 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054326 | 0.82 | DHFR (0.46) | DHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9547681 | 0.80 | DHFR (0.45) | DHFR | |
| SCHEMBL9547703 | 0.75 | HPGD (0.43) | DHFR | |
| SCHEMBL15055063 | 0.75 | DHFR (0.38) | DHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9542041 | 0.72 | DHFR (0.52) | DHFR | |
| SCHEMBL17562254 | 0.72 | DHFR (0.46) | DHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL17554417 | 0.71 | DHFR (0.46) | DHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL17554406 | 0.71 | DHFR (0.46) | DHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL17554357 | 0.71 | DHFR (0.46) | DHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9541999 | 0.71 | DHFR (0.66) | DHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440979-B2 | Process for the preparation of pralatrexate | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-9440979-B2 | Process for the preparation of pralatrexate | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| EP-2794610-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING PRALATREXATE | PLUS CHEMICALS SA (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20150183789-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| US-20150183789-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| EP-2794610-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING PRALATREXATE | Plus Chemicals SA (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096800-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING PRALATREXATE | PLUS CHEMICALS S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096800-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING PRALATREXATE | PLUS CHEMICALS S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183789-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE | CYP3A5, UGT1A4, UGT1A3 | DHFR 24/4885FOLR1 182/4885SLC19A1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.